{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:07:20Z","timestamp":1787836040753,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T00:00:00Z","timestamp":1424822400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1007\/s12031-015-0517-6","type":"journal-article","created":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T07:29:41Z","timestamp":1424762981000},"page":"577-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease Severity"],"prefix":"10.1007","volume":"56","author":[{"given":"Iria V.","family":"Seoane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Tomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Garcia-Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Juarranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Lamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Oc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"G\u00f3mez-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidoro","family":"Gonz\u00e1lez-\u00c1lvaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa P.","family":"Gomariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"key":"517_CR1","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/gast.2003.50141","volume":"124","author":"C Abad","year":"2003","unstructured":"Abad C, Martinez C, Juarranz MG et al (2003) Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn\u2019s disease. Gastroenterology 124:961\u2013971","journal-title":"Gastroenterology"},{"key":"517_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10067-013-2349-5","volume":"33","author":"R Almodovar","year":"2014","unstructured":"Almodovar R, Rios V, Ocana S et al (2014) Association of biomarkers of inflammation, cartilage and bone turnover with gender, disease activity, radiological damage and sacroiliitis by magnetic resonance imaging in patients with early spondyloarthritis. Clin Rheumatol 33:237\u2013241","journal-title":"Clin Rheumatol"},{"key":"517_CR3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/art.24493","volume":"60","author":"AN Bennett","year":"2009","unstructured":"Bennett AN, Rehman A, Hensor EM, Marzo-Ortega H, Emery P, McGonagle D (2009) Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 60:1331\u20131341","journal-title":"Arthritis Rheum"},{"key":"517_CR4","first-page":"S16","volume":"20","author":"J Braun","year":"2002","unstructured":"Braun J, Pincus T (2002) Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 20:S16\u201322","journal-title":"Clin Exp Rheumatol"},{"key":"517_CR5","first-page":"2281","volume":"21","author":"A Calin","year":"1994","unstructured":"Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281\u20132285","journal-title":"J Rheumatol"},{"key":"517_CR6","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1136\/ard.60.11.1040","volume":"60","author":"L Carmona","year":"2001","unstructured":"Carmona L, Ballina J, Gabriel R, Laffon A (2001) The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. Ann Rheum Dis 60:1040\u20131045","journal-title":"Ann Rheum Dis"},{"key":"517_CR7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/art.30294","volume":"63","author":"M Carrion","year":"2011","unstructured":"Carrion M, Juarranz Y, Perez-Garcia S et al (2011) RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 63:1626\u20131636","journal-title":"Arthritis Rheum"},{"key":"517_CR8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12031-013-0177-3","volume":"52","author":"M Carrion","year":"2014","unstructured":"Carrion M, Juarranz Y, Seoane IV et al (2014) VIP modulates IL-22R1 expression and prevents the contribution of rheumatoid synovial fibroblasts to IL-22-mediated joint destruction. J Mol Neurosci 52:10\u201317","journal-title":"J Mol Neurosci"},{"key":"517_CR9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.0105-2896.2009.00865.x","volume":"233","author":"RA Colbert","year":"2010","unstructured":"Colbert RA, DeLay ML, Klenk EI, Layh-Schmitt G (2010) From HLA-B27 to spondyloarthritis: a journey through the ER. Immunol Rev 233:181\u2013202","journal-title":"Immunol Rev"},{"key":"517_CR10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","volume":"71","author":"HY Chung","year":"2012","unstructured":"Chung HY, Machado P, van der Heijde D, D\u2019Agostino MA, Dougados M (2012) Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis 71:809\u2013816","journal-title":"Ann Rheum Dis"},{"key":"517_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.berh.2010.05.009","volume":"24","author":"K Vlam de","year":"2010","unstructured":"de Vlam K (2010) Soluble and tissue biomarkers in ankylosing spondylitis. Best Pract Res Clin Rheumatol 24:671\u2013682","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"517_CR12","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/87887","volume":"7","author":"M Delgado","year":"2001","unstructured":"Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 7:563\u2013568","journal-title":"Nat Med"},{"key":"517_CR13","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM200102013440508","volume":"344","author":"RA Deyo","year":"2001","unstructured":"Deyo RA, Weinstein JN (2001) Low back pain. N Engl J Med 344:363\u2013370","journal-title":"N Engl J Med"},{"key":"517_CR14","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(11)60071-8","volume":"377","author":"M Dougados","year":"2011","unstructured":"Dougados M, Baeten D (2011) Spondyloarthritis. Lancet 377:2127\u20132137","journal-title":"Lancet"},{"key":"517_CR15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/rheumatology\/ker319","volume":"51","author":"I Fabreguet","year":"2012","unstructured":"Fabreguet I, Koumakis E, Burki V et al (2012) Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scale. Rheumatology (Oxford) 51:333\u2013337","journal-title":"Rheumatology (Oxford)"},{"key":"517_CR16","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/ket233","volume":"52","author":"DE Furst","year":"2013","unstructured":"Furst DE, Kay J, Wasko MC et al (2013) The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford) 52:1845\u20131855","journal-title":"Rheumatology (Oxford)"},{"key":"517_CR17","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"517_CR18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1196\/annals.1317.031","volume":"1070","author":"RP Gomariz","year":"2006","unstructured":"Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C (2006) VIP-PACAP system in immunity: new insights for multitarget therapy. Ann N Y Acad Sci 1070:51\u201374","journal-title":"Ann N Y Acad Sci"},{"key":"517_CR19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/kei219","volume":"45","author":"I Gutierrez-Canas","year":"2006","unstructured":"Gutierrez-Canas I, Juarranz Y, Santiago B et al (2006) VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts. Rheumatology (Oxford) 45:527\u2013532","journal-title":"Rheumatology (Oxford)"},{"key":"517_CR20","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.bbi.2007.09.007","volume":"22","author":"I Gutierrez-Canas","year":"2008","unstructured":"Gutierrez-Canas I, Juarranz Y, Santiago B et al (2008) Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav Immun 22:312\u2013317","journal-title":"Brain Behav Immun"},{"key":"517_CR21","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.clinbiochem.2012.08.020","volume":"45","author":"W Jiang","year":"2012","unstructured":"Jiang W, Gao SG, Chen XG et al (2012) Expression of synovial fluid and articular cartilage VIP in human osteoarthritic knee: a new indicator of disease severity? Clin Biochem 45:1607\u20131612","journal-title":"Clin Biochem"},{"key":"517_CR22","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/icb.2010.29","volume":"88","author":"R Jimeno","year":"2010","unstructured":"Jimeno R, Gomariz RP, Gutierrez-Canas I, Martinez C, Juarranz Y, Leceta J (2010) New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 88:734\u2013745","journal-title":"Immunol Cell Biol"},{"key":"517_CR23","doi-asserted-by":"crossref","first-page":"R1034","DOI":"10.1186\/ar1779","volume":"7","author":"Y Juarranz","year":"2005","unstructured":"Juarranz Y, Abad C, Martinez C et al (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 7:R1034\u20131045","journal-title":"Arthritis Res Ther"},{"key":"517_CR24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/annrheumdis-2011-200508","volume":"71","author":"U Kiltz","year":"2012","unstructured":"Kiltz U, Baraliakos X, Karakostas P et al (2012) The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis 71:1207\u20131211","journal-title":"Ann Rheum Dis"},{"key":"517_CR25","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/ard.2008.091793","volume":"68","author":"R Landewe","year":"2009","unstructured":"Landewe R, Dougados M, Mielants H, van der Tempel H, van der Heijde D (2009) Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis 68:863\u2013867","journal-title":"Ann Rheum Dis"},{"key":"517_CR26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000110636","volume":"14","author":"J Leceta","year":"2007","unstructured":"Leceta J, Gomariz RP, Martinez C, Carrion M, Arranz A, Juarranz Y (2007) Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 14:134\u2013138","journal-title":"Neuroimmunomodulation"},{"key":"517_CR27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s10875-006-9042-2","volume":"26","author":"H Li","year":"2006","unstructured":"Li H, Mei Y, Wang Y, Xu L (2006) Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 26:430\u2013437","journal-title":"J Clin Immunol"},{"key":"517_CR28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/ard.2005.038232","volume":"65","author":"BM Lodde","year":"2006","unstructured":"Lodde BM, Mineshiba F, Wang J et al (2006) Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren\u2019s syndrome. Ann Rheum Dis 65:195\u2013200","journal-title":"Ann Rheum Dis"},{"key":"517_CR29","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"MADA Machado","year":"2013","unstructured":"Machado MADA, Barbosa MM, Almeida AM et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33:2199\u20132213","journal-title":"Rheumatol Int"},{"key":"517_CR30","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1136\/annrheumdis-2012-201999","volume":"71","author":"P Machado","year":"2012","unstructured":"Machado P, Landewe RB, Braun J et al (2012) MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Ann Rheum Dis 71:2002\u20132005","journal-title":"Ann Rheum Dis"},{"key":"517_CR31","doi-asserted-by":"crossref","first-page":"e85248","DOI":"10.1371\/journal.pone.0085248","volume":"9","author":"C Martinez","year":"2014","unstructured":"Martinez C, Ortiz AM, Juarranz Y et al (2014) Serum levels of vasoactive intestinal Peptide as a prognostic marker in early arthritis. PLoS One 9:e85248","journal-title":"PLoS One"},{"key":"517_CR32","first-page":"1583","volume":"29","author":"H Marzo-Ortega","year":"2002","unstructured":"Marzo-Ortega H, Emery P, McGonagle D (2002) The concept of disease modification in spondyloarthropathy. J Rheumatol 29:1583\u20131585","journal-title":"J Rheumatol"},{"key":"517_CR33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/ard.2008.097931","volume":"68","author":"H Marzo-Ortega","year":"2009","unstructured":"Marzo-Ortega H, McGonagle D, O\u2019Connor P et al (2009) Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 68:1721\u20131727","journal-title":"Ann Rheum Dis"},{"key":"517_CR34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/annrheumdis-2013-203924","volume":"73","author":"D McGonagle","year":"2014","unstructured":"McGonagle D, Thomas RC, Schett G (2014) Spondyloarthritis: may the force be with you? Ann Rheum Dis 73:321\u2013323","journal-title":"Ann Rheum Dis"},{"key":"517_CR35","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00296-010-1417-2","volume":"31","author":"S Nalbant","year":"2011","unstructured":"Nalbant S, Cagiltay E, Sahan B, Terekeci HM, Oktenli C (2011) The vasoactive intestinal polypeptide (VIP) levels at the patients with ankylosing spondylitis and its association with inflammation markers. Rheumatol Int 31:1143\u20131146","journal-title":"Rheumatol Int"},{"key":"517_CR36","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1756-185X.2011.01662.x","volume":"15","author":"L Niccoli","year":"2012","unstructured":"Niccoli L, Nannini C, Cassara E, Kaloudi O, Cantini F (2012) Frequency of anemia of inflammation in patients with ankylosing spondylitis requiring anti-TNFalpha drugs and therapy-induced changes. Int J Rheum Dis 15:56\u201361","journal-title":"Int J Rheum Dis"},{"key":"517_CR37","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.0006-341X.2001.00529.x","volume":"57","author":"W Pan","year":"2001","unstructured":"Pan W (2001) Model selection in estimating equations. Biometrics 57:529\u2013534","journal-title":"Biometrics"},{"key":"517_CR38","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J et al (2012) Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 64:1388\u20131398","journal-title":"Arthritis Rheum"},{"key":"517_CR39","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1136\/ard.2009.110767","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, Jurik AG, Hermann KG et al (2009a) Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS\/OMERACT MRI group. Ann Rheum Dis 68:1520\u20131527","journal-title":"Ann Rheum Dis"},{"key":"517_CR40","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/art.20990","volume":"52","author":"M Rudwaleit","year":"2005","unstructured":"Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 52:1000\u20131008","journal-title":"Arthritis Rheum"},{"key":"517_CR41","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landewe R et al (2009b) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"517_CR42","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","volume":"70","author":"D Heijde van der","year":"2011","unstructured":"van der Heijde D, Sieper J, Maksymowych WP et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70:905\u2013908","journal-title":"Ann Rheum Dis"},{"key":"517_CR43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"517_CR44","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1136\/ard.2010.147744","volume":"70","author":"N Vastesaeger","year":"2011","unstructured":"Vastesaeger N, van der Heijde D, Inman RD et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70:973\u2013981","journal-title":"Ann Rheum Dis"},{"key":"517_CR45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/acr.21821","volume":"65","author":"MM Ward","year":"2013","unstructured":"Ward MM, Learch TJ, Gensler LS, Davis JC Jr, Reveille JD, Weisman MH (2013) Regional radiographic damage and functional limitations in patients with ankylosing spondylitis: differences in early and late disease. Arthritis Care Res (Hoboken) 65:257\u2013265","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-015-0517-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-015-0517-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-015-0517-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T23:16:16Z","timestamp":1553642176000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-015-0517-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1007\/s12031-015-0517-6","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]}}}